Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.0040.000190%Not Available
Maculopathy06.09.03.0070.001012%Not Available
Malaise08.01.01.0030.000443%
Meningitis17.06.03.001; 11.01.03.001--
Menstrual disorder21.01.01.0040.000126%Not Available
Menstruation irregular21.01.01.005; 05.05.01.0080.000316%
Metrorrhagia21.01.01.0060.000126%Not Available
Migraine24.03.05.003; 17.14.02.0010.000190%Not Available
Miliaria23.02.03.014--Not Available
Monoplegia17.01.04.003--Not Available
Mood swings19.04.03.001--Not Available
Muscle atrophy17.05.03.004; 15.05.03.0030.000379%Not Available
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.0050.000126%
Musculoskeletal pain15.03.04.0070.000253%
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture12.01.11.002; 02.04.02.002--Not Available
Myopathy15.05.05.001--Not Available
Nasal dryness22.04.03.0020.000126%Not Available
Nasal oedema22.04.03.0120.000126%Not Available
Nasal septum perforation22.04.03.003--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.0020.000126%Not Available
Nausea07.01.07.001--
Neck pain15.03.04.0090.000126%
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nitrogen balance negative13.13.01.010--Not Available
Ocular hyperaemia06.04.05.0040.000190%Not Available
Ocular hypertension06.03.01.0030.000126%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages